In the latest weekly data update, Eli Lilly's quality score advanced from 89.66 to 90.04. This uptick pushes the stock into the “elite” tier of the market, ranking it higher than 90% of its peers.
The obesity and diabetes drug boom is no longer a one-cycle story. Demand for GLP-1 treatments continues to exceed supply, with physicians expanding use beyond diabetes into weight management and ...
We recently published 8 Stocks on Jim Cramer’s Radar. Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer's radars. Eli Lilly and Company (NYSE:LLY) is another top Cramer healthcare ...
Hosted on MSN
Eli Lilly and Company (LLY) announces updated meaningful data on breast cancer treatment
Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy according to hedge funds. On December 15, Goldman Sachs lifted its price target on Eli Lilly and Company (NYSE:LLY) to $1,145 ...
Pharmaceutical giant Novo Nordisk just earned approval for an oral version of Wegovy. This could help improve its position in the increasingly competitive weight loss market. Despite some headwinds, ...
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback